(Total Views: 518)
Posted On: 01/18/2020 6:11:31 AM
Post# of 153864
Re: Cytodynamite #15366
NK
From a quick look at the MOA - PD-L1.t-haNK is an amped up Keytruda. Extremely effective in bladder cancers and very effective (50%) in lymphoma. Other cancers around 20% - 25% CR. Impressive results.
Leronlimab downregulates PD-L1 along with many other MOAs. Hopefully they're testing for PD-L1 levels in the mTNBC trial. This would give us an indication if a PD-L1 inhibitor would boost our responses or not.
A PD-L1 inhibitor may aid leronlimab but it won't supplant it.
From a quick look at the MOA - PD-L1.t-haNK is an amped up Keytruda. Extremely effective in bladder cancers and very effective (50%) in lymphoma. Other cancers around 20% - 25% CR. Impressive results.
Leronlimab downregulates PD-L1 along with many other MOAs. Hopefully they're testing for PD-L1 levels in the mTNBC trial. This would give us an indication if a PD-L1 inhibitor would boost our responses or not.
A PD-L1 inhibitor may aid leronlimab but it won't supplant it.
(2)
(0)
